Who’s Who in All-Oral HCV Programs [Updated status of IDIX entry.][pre] Protease Other Non-PI Dosing Company Inhibitor Compound Class Frequency Link VRTX Telaprevir VX-222 non-nuke BID http://clinicaltrials.gov/ct2/show/NCT01080222 Roche ITMN-191 RG7128 nuke TID/BID http://clinicaltrials.gov/ct2/show/NCT00801255 BMY BMS-650032 BMS-790052 NS5A BID http://clinicaltrials.gov/ct2/show/NCT01012895 B-I BI 201335 BI 207127 non-nuke TID/BID http://clinicaltrials.gov/ct2/show/NCT01132313 IDIX† IDX320 IDX184 nuke qD † ACHN ACH-1625 ACH-2928 NS5A qD * VRUS n/a PSI-7977 nuke/nuke qD * +PSI-938 [/pre]*All-oral trial has not started. †Program on clinical hold pending FDA review of SAE’s in drug-drug-interaction study.